Complete cytogenietic remission with imatinib mesylate treatment in chronic myelogenous leukemia (CML) developed after renal transplantation.

Koca, E; Cetiner, D; Goker, H; Aksu, S; Ozcebe, O I; Haznedaroglu, I C; Turgan, C

Koca, E; Cetiner, D; Goker, H; Aksu, S; Ozcebe, O I; Haznedaroglu, I C; Turgan, C.

Clin Nephrol ; 64(4): 324-6, 2005 Oct.

Article in En | MEDLINE | ID: mdl-16240908

Subject(s)

Antineoplastic Agents/therapeutic use; Bone Marrow/pathology; Kidney Transplantation/adverse effects; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy; Piperazines/therapeutic use; Protein-Tyrosine Kinases/antagonists & inhibitors; Pyrimidines/therapeutic use; Adult; Benzamides; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/etiology; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology; Male; Philadelphia Chromosome; Remission Induction

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Piperazines / Pyrimidines / Bone Marrow / Protein-Tyrosine Kinases / Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Kidney Transplantation / Antineoplastic Agents Type of study: Etiology_studies / Observational_studies / Prognostic_studies Limits: Adult / Humans / Male Language: En Journal: Clin Nephrol Year: 2005 Document type: Article

Search on Google

Add to My VHL

XML

PubMed Links